- For more than 20 years, our now open access journal has published discoveries in molecular medicine for a multidisciplinary audience.
- The journal is managed by experts at the Feinstein Institutes for Medical Research. In collaboration with the Institutes, the journal’s two awards celebrate innovation and support researchers: The Ross Prize in Molecular Medicine and the Anthony Cerami Award in Translational Medicine.
- We provide authors with a variety of options for communicating important novel insights from pre-clinical and clinical research, and advances in the field.
Aims and scope
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.
Criteria to consider for studies involving lnc-RNAs or micro-RNAs:
· As lncRNAs and miRNAs have multiple targets, claims of their function mediated by a single target or pathway will not be accepted, unless multiple additional targets are investigated to support functional specificity.
· The rationale to investigate a specific lncRNA or miRNA needs to be specified upfront in the introduction and justified in the context of other miRNAs known to be functional in that specific field.
· The proposed function of the lnc-RNA or miRNA should be validated by gain and loss of function studies.
· Primary cells should be used whenever possible to confirm findings in cell lines.
· In depth investigation in the signaling pathway(s) regulated by the RNA species should be conducted.
· Insight into the regulation of the RNA species and how it relates to the pathologic state should be provided.
· If applicable: Details of initial screen used to identify RNA species involvement in pathway/disease (number of subjects, statistical tests employed, percent change from controls).
Why publish your article in Molecular Medicine?
All articles published by Molecular Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Molecular Medicine you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.
Benefits of publishing with BMC
Molecular Medicine's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Molecular Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Molecular Medicine gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Molecular Medicine are included in article alerts and regular email updates. Some may be highlighted on Molecular Medicine’s pages and on the BMC homepage.
In addition, articles published in Molecular Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Medicine. A list of articles recently press-released by journals published by BMC is available here.
As an author of an article published in Molecular Medicine you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).
For further information about the advantages of publishing in a journal from BMC, please click here.
Article processing charges (APC)
Authors who publish open access in Molecular Medicine are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.
The current APC, subject to VAT or local taxes where applicable, is: £2190.00/$2990.00/€2490.00
For information about the APC applicable for articles accepted for publication next year, please see our journal lists.
Open access funding
Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.
Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.
A note to authors from the Feinstein Institutes: please do not submit a manuscript with a membership code, without being invited to do so by our editors. Feinstein authorship does not automatically warrant use of a membership code.
All articles published in Molecular Medicine are included in:
- PubMed Central
- Web of Science
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Molecular Medicine operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. Authors are allowed to suggest up to three potential reviewers in their cover letter, but they should not suggest recent collaborators (individuals they wrote with, within the last three years) or colleagues who work in the same institution as themselves (and they will not find out which reviewers were invited).
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Molecular Medicine should adhere to BMC's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Molecular Medicine
Articles in Molecular Medicine should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Mol Med [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Med 2009, 1:115.
1:115 refers to article 115 from Volume 1 of the journal.
Appeals and complaints
About Feinstein Institutes for Medical Research
Molecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.
Annual Journal Metrics
Annual Journal Metrics
2022 Citation Impact
5.7 - 2-year Impact Factor
6.3 - 5-year Impact Factor
1.026 - SNIP (Source Normalized Impact per Paper)
1.245 - SJR (SCImago Journal Rank)
8 days submission to first editorial decision for all manuscripts (Median)
122 days submission to accept (Median)
5,337 Altmetric mentions